Carole Pissot-Soldermann

发表

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

D. Erdmann, J. Brueggen, P. Furet, 2010, Molecular Cancer Therapeutics.

Stabilizing Inactive Conformations of MALT1 as an Effective Approach to Inhibit Its Protease Activity

M. Renatus, C. Wiesmann, F. Villard, 2020 .

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

A short and concise asymmetric synthesis of hamigeran B.

B. Trost, Irwin Chen, Carole Pissot-Soldermann, 2005, Chemistry.

An asymmetric synthesis of hamigeran B via a Pd asymmetric allylic alkylation for enantiodiscrimination.

B. Trost, Irwin Chen, G. M. Schroeder, 2004, Journal of the American Chemical Society.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

The T‐cell fingerprint of MALT1 paracaspase revealed by selective inhibition

G. Bold, M. Renatus, J. Kovarik, 2018, Immunology and cell biology.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

W. Sellers, R. Levine, F. Hofmann, 2012, Cancer discovery.

Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing.

P. Furet, M. Gerspacher, Carole Pissot-Soldermann, 2010, Bioorganic & medicinal chemistry letters.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.

A. Schuffenhauer, Philipp Holzer, N. Schmiedeberg, 2023, ACS Medicinal Chemistry Letters.